| Literature DB >> 33321094 |
Irene Gallina1, Ivo A Hendriks1, Saskia Hoffmann1, Nicolai B Larsen1, Joachim Johansen1, Camilla S Colding-Christensen1, Lisa Schubert1, Selene Sellés-Baiget1, Zita Fábián1, Ulrike Kühbacher1, Alan O Gao1, Markus Räschle2, Simon Rasmussen1, Michael L Nielsen1, Niels Mailand1, Julien P Duxin3.
Abstract
Lesions on DNA uncouple DNA synthesis from the replisome, generating stretches of unreplicated single-stranded DNA (ssDNA) behind the replication fork. These ssDNA gaps need to be filled in to complete DNA duplication. Gap-filling synthesis involves either translesion DNA synthesis (TLS) or template switching (TS). Controlling these processes, ubiquitylated PCNA recruits many proteins that dictate pathway choice, but the enzymes regulating PCNA ubiquitylation in vertebrates remain poorly defined. Here we report that the E3 ubiquitin ligase RFWD3 promotes ubiquitylation of proteins on ssDNA. The absence of RFWD3 leads to a profound defect in recruitment of key repair and signaling factors to damaged chromatin. As a result, PCNA ubiquitylation is inhibited without RFWD3, and TLS across different DNA lesions is drastically impaired. We propose that RFWD3 is an essential coordinator of the response to ssDNA gaps, where it promotes ubiquitylation to drive recruitment of effectors of PCNA ubiquitylation and DNA damage bypass.Entities:
Keywords: CHROMASS; DPC repair; HMCES; ICL repair; PCNA; RFWD3; TLS; UV lesions; anemia; ubiquitylation
Year: 2020 PMID: 33321094 PMCID: PMC7864614 DOI: 10.1016/j.molcel.2020.11.029
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970
Figure 1RFWD3 is essential for TLS across peptide adducts
(A) Heatmap depicting the mean of the Z score, log2, label-free quantification (LFQ) intensity from four biochemical replicates of pCTRL and pDPCLeads (originally published in Larsen et al., 2019). Red arrow indicates RFWD3. Geminin was added to block DNA replication. Ubiquitin-vinyl sulfone (UbVS) was added to deplete the pool of free ubiquitin.
(B) Replication intermediates generated during replication of pMH (Duxin et al., 2014).
(C) pMH was replicated in egg extracts in the presence of [α-32P]dATP in mock- or RFWD3-depleted extracts. Reaction samples were analyzed by native agarose gel electrophoresis. RI, replication intermediate; OC, open circular; SC, supercoiled. Red arrowheads indicate OC molecules. Lower graph: quantification of replication efficiencies from three independent experiments. Error bars represent the standard error of the mean (SEM). To deplete RFWD3, the RFWD3-N antibody was used in all experiments unless otherwise indicated.
(D) Nascent leading strand and extension products generated upon FspI and AatII digest of pMH. Double digestion generates shorter damaged and longer undamaged extension products, which can be resolved on a denaturing polyacrylamide gel (see E, top panel). The CMG helicase is depicted in green, and the crosslinked M.HpaII is depicted in gray.
(E) Samples from (C) were digested with FspI and AatII (upper panel) or AatII (lower panel) and separated on a denaturing polyacrylamide gel. Location of the stalling points in relation to the DPC is indicated on the right of the gel.
(F) Generation of pMHPK.
(G) pMHPK was replicated in mock- or RFWD3-depleted extracts and analyzed as in (C).
(H) Samples from (G) were analyzed as in (E).
(I) pMHPK-Lead or pMHPK-Lag were replicated in egg extracts in the presence of LacI. Samples were digested with FspI and AatII (upper panel) or either AatII (pMHPK-Lead, lower panel) or BssHII (pMHPK-Lag, lower panel) and analyzed as in (E).
Figure 2Replication of pMH is a two-step mutagenic process
(A) pMH was replicated in mock-, Polη-, REV1-, or Polη- and REV1-depleted extracts. Samples were analyzed as in Figure 1C.
(B) Samples from (A) were digested and analyzed as in Figure 1E. U, undamaged strand; D, damaged strand.
(C) pMH was replicated in mock-, Polη-, RFWD3-, or Polη- and RFWD3-depleted extracts. Samples were analyzed as in Figure 1E.
(D) Quantification of mutation frequencies measured after replication of pCTRL or pMH. Replication samples were amplified by PCR and analyzed by next-generation sequencing (see STAR methods). The 0 position corresponds to the location of the protein adduct. One of three independent experiments is shown.
(E) Distribution of nucleotide misincorporation from the data generated in (D).
(F) pMH was replicated in either mock- or Polη-depleted extracts, and samples were amplified and analyzed as in (D). One of three independent experiments is shown.
(G) Distribution of nucleotide misincorporation from the data generated in (F).
Figure 3RFWD3 is essential for DNA synthesis across different polymerase-stalling DNA lesions
(A) pCTRLssDNA or pCPDssDNA were incubated in non-licensing egg extracts in the presence of [α-32P]dATP. Samples were analyzed on a denaturing polyacrylamide gel following AatII-ApoI digest. Top scheme: extension products generated by AatII-ApoI digest.
(B) pCPDssDNA was incubated in mock-, Polη-, REV1-, or RFWD3-depleted non-licensing extracts. Samples were analyzed as in (A). Quantification of the relative intensity of the −1 product for three independent experiments is shown in the lower panel. Intensity of the −1 product was quantified for each lane and normalized to the maximum value. Error bars represent SEM.
(C) pICLpt was replicated in mock- or RFWD3-depleted extracts (with either the RFWD3-N or the RFWD3-F antibody), in the presence of pQuant. Reaction samples were analyzed by native agarose gel electrophoresis.
(D) Intermediates generated by AflIII digest on pICLpt.
(E) Samples from (C) were digested with AflIII and analyzed on a denaturing polyacrylamide gel.
Figure 4RFWD3 regulates PCNA ubiquitylation
(A) pMHLeads was replicated in mock- or RFWD3-depleted extracts and analyzed as in Figure 1C (upper panel) or blotted with the indicated antibodies (bottom three panels). Asterisks indicate unspecific bands.
(B) pMH or pMHPK were replicated in the presence or absence of ubiquitin E1 inhibitor. Reaction samples were digested and analyzed as in Figure 1E.
(C) Sperm chromatin was either untreated or treated with 20 J/m2 UV-C and then replicated in egg extracts. A CDC7 inhibitor was added to block origin firing and DNA replication. Proteins associated with isolated chromatin were blotted with the indicated antibodies. Red dots correspond to PCNA ubiquitylation (likely mono-, di-, and tri-ubiquitin). The black dot corresponds to mono-sumoylated PCNA (see Figure S4K for bands assignment).
(D) Sperm chromatin was either untreated or treated with 20 J/m2 UV-C and then replicated in mock- or RFWD3-depleted extracts. Chromatin was isolated, and the proteins associated were blotted with the indicated antibodies. The percentage of ubiquitylated PCNA over unmodified PCNA is indicated underneath the PCNA blot.
(E) pCTRL or pMHLeads were replicated in egg extracts and analyzed as in Figure 1C.
(F) Reactions from (E) were subjected to plasmid pull-down, and samples were blotted with the indicated antibodies.
(G) pMHLeads was replicated in mock-, RFWD3-, or REV1-depleted extracts. Reactions were processed as in (F). The percentage of ubiquitylated PCNA over unmodified PCNA is indicated.
Figure 5RFWD3 ubiquitin ligase activity regulates PCNA ubiquitylation in human cells
(A) U2OS cells or U2OS cells expressing Strep-HA-PCNA were transfected with siCtrl or 4 different siRNAs against RFWD3 and either left untreated or treated with UV (30 J/m2). PCNA was recovered under denaturing conditions via Strep-Tactin pull-down and analyzed by immunoblotting with the indicated antibodies.
(B) U2OS cells or U2OS/FRT GFP-RFWD3 WT or catalytic inactive (C315A) cells were treated with the indicated siRNAs, transfected with either empty vector (EV) or Strep-HA-PCNA plasmids, and treated with doxycycline to induce expression of RFWD3. UV treatment and protein pull-down were performed as in (A).
(C) U2OS cells were transfected with the indicated plasmids and then subjected to Strep-Tactin pull-down as in (A).
(D) U2OS/FRT GFP-RFWD3 WT cells were treated with doxycycline and transfected with EV or Strep-HA-PCNA 24 h before lysis in denaturing buffer. Lysates were subjected to Strep-Tactin pull-down in denaturing conditions, washed, and incubated with USP2 (ubiquitin protease) and/or UPL1 (SUMO protease), as indicated.
(E) U2OS cells or U2OS/FRT GFP-RFWD3 WT cells were transfected with either control (siCtrl) or RAD18 siRNAs. After 48 h, cells were transfected with either EV or Strep-HA-PCNA plasmids and treated with doxycycline to induce the expression RFWD3 WT. Then, cells were treated with UV for 4 h and processed for Strep-Tactin pull-down as described in (A). The asterisk denotes a non-specific band.
Figure 6RFWD3 regulates ubiquitin levels and protein recruitment to UV damaged chromatin
(A) MS analysis of protein recruitment to UV-treated sperm chromatin in mock- or REV1-depleted extracts. The volcano plot shows the difference in abundance of proteins between the two sample conditions (x axis), plotted against the p value resulting from two-tailed Student’s t testing (y axis). Proteins significantly down- or upregulated (false discovery rate [FDR] < 5%) in REV1-depleted reactions are represented in red or blue, respectively. n = 4 biochemical replicates. FDR < 5% corresponds to permutation-based, FDR-adjusted q < 0.05. Different isoforms of the same protein can be detected (e.g., REV1).
(B) Same experiment as in (A) but comparing mock- to RFWD3-depleted extracts. Small red dots, 1% < FDR < 5%; large red dots, FDR < 1%.
(C) STRING network of proteins highly significantly upregulated (FDR < 1%) on UV-treated sperm chromatin compared with mock-treated chromatin and highly significantly downregulated (FDR < 1%) on UV-treated sperm chromatin with RFWD3 depletion compared with mock depletion.
(D) An independent experiment was analyzed by immunoblot using the indicated antibodies.
(E) Average PCNA and PCNA K164-ubiquitin abundance on sperm chromatin identified by tandem mass spectrometry (MS/MS), quantified in a label-free manner, and plotted as a ratio over untreated control. n = 4 biochemical replicates. Error bars represent SEM. ∗∗p < 0.01, via two-tailed Student’s t testing.
(F) Quantification of ubiquitin linkages on sperm chromatin directly identified by MS/MS via diglycine-modified lysine residues in the corresponding peptide sequences and quantified in a label-free manner. n = 4 biochemical replicates. Error bars represent SEM. ∗p < 0.05, ∗∗p < 0.01, via two-tailed Student’s t testing.
Figure 7RFWD3 simulates ubiquitylation of proteins on ssDNA
(A) Fpg bacterial glycosylase was crosslinked to either double-stranded (pFpg) or single-stranded DNA (pFpgssDNA) and added to SPRTN-depleted non-licensing egg extracts. DPC pull-down under stringent conditions was performed at the indicated time points, and samples were blotted against crosslinked Fpg. Slow mobility bands represent ubiquitylated Fpg species (see B).
(B) pFpgssDNA was incubated in SPRTN-depleted non-licensing extracts, and ubiquitin E1 inhibitor was added where indicated. Plasmids were recovered, and samples were blotted against Fpg as in (A).
(C) pFpgssDNA was incubated in mock- or RFWD3-depleted non-licensing extracts (also depleted of SPRTN) for the indicated time points and samples processed as in (A).
(D) Generation of an AP site on ssDNA (pAPssDNA) to induce HMCES crosslinking.
(E) pAPssDNA was incubated in SPRTN-depleted non-licensing extracts, and ubiquitin E1 inhibitor was added where indicated. Plasmids were recovered, and proteins were blotted against HMCES. The black dot indicates sumoylated HMCES (see F).
(F) pAPssDNA was incubated in mock- or RFWD3-depleted non-licensing extracts (depleted of SPRTN), and ubiquitin E1 inhibitor or SUMO E1 inhibitor was added where indicated. Plasmids were recovered and analyzed as in (D).
(G) Model illustrating the role of RFWD3 in gap-filling DNA synthesis (see Discussion).
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Rabbit polyclonal anti-Rev1-N | N/A | |
| Rabbit polyclonal anti-Rev1-C | N/A | |
| Rabbit polyclonal anti-Rev7 | N/A | |
| Rabbit polyclonal anti-PCNA | N/A | |
| Rabbit polyclonal anti-Fancd2 | N/A | |
| Rabbit polyclonal anti-Cdt1 | N/A | |
| Rabbit polyclonal anti-MCM6 | 2926 | |
| Rabbit polyclonal anti-RPA | N/A | |
| Rabbit polyclonal anti-TraiP | 3472 | |
| Rabbit polyclonal anti-BRCA1 | N/A | |
| Rabbit polyclonal anti-Sprtn | 3703 | |
| Rabbit polyclonal anti-M.HpaII | N/A | |
| Rabbit polyclonal anti-phospho-Chk1 (S345) | Cell Signaling Technology | Cat#2341; RRID: |
| Rabbit polyclonal anti-histone H3 | Cell Signaling Technology | Cat#9715; RRID: |
| Rabbit monoclonal antibody anti-ubiquityl-PCNA (K164) (D5C7P) | Cell Signaling Technology | Cat#13439; RRID: |
| Rabbit polyclonal anti-Polη | This paper | 3923 |
| Rabbit polyclonal anti-HMCES | This paper | 4639 |
| Rabbit polyclonal anti-Rfwd3-N | This paper | 3575 and 4056 |
| Rabbit polyclonal anti-Ubc13 | This paper | 4262 |
| Rabbit polyclonal anti-PolD1 | This paper | 4000 |
| Rabbit polyclonal anti-PolD2 | This paper | 4516 |
| Rabbit polyclonal anti-PolD3 | This paper | 4517 |
| Rabbit polyclonal anti-Rad6 | This paper | 4266 |
| Rabbit polyclonal anti-Polκ | This paper | 3924 |
| Rabbit polyclonal anti-Zranb3 | This paper | 4057 |
| Rabbit polyclonal anti-Nse2 | This paper | 3484 |
| Rabbit polyclonal anti-Rad18 | This paper | 4265 |
| Rabbit polyclonal anti-RPA-70 | This paper | 4495 |
| Rabbit polyclonal anti-RPA-14 | This paper | 4493 |
| Rabbit polyclonal anti-Wrnip1 | This paper | 4082 |
| Rabbit polyclonal anti-Rfwd3-F | This paper | N/A |
| Mouse monoclonal anti-GFP | Roche | Cat#11814460001; RRID: |
| Rabbit polyclonal anti-GFP | Santa Cruz Biotachnology | Cat#sc-8334; RRID: |
| Rabbit polyclonal anti-HA | Santa Cruz Biotachnology | Cat#sc-805; RRID: |
| Goat polyclonal antibody anti MCM6 | Santa Cruz Biotachnology | Cat#sc-9843; RRID: |
| Rabbit polyclonal antibody anti RAD18 | Bethyl Laboratories | Cat#A301-340A; RRID: |
| Goat polyclonal antibody anti HLTF | Santa Cruz Biotachnology | Cat#sc-27542; RRID: |
| Rabbit polyclonal antibody anti SHPRH | abcam | Cat#ab80129; RRID: |
| Rabbit polyclonal antibody anti RFWD3 | abcam | Cat#ab138030; RRID: |
| Rabbit polyclonal antibody anti UBC13 | Cell Signaling Technology | Cat#4919; RRID: |
| Mouse monoclonal antibody anti ubiquitin | Santa Cruz Biotachnology | Cat#sc-8017; RRID: |
| Mouse monoclonal antibody anti vinculin | Sigma-Aldrich | Cat#V9131; RRID: |
| MLN-7243 Ubiquitin E1 inhibitor | Active Biochem | Cat#A-1384; CAS:1450833-55-2 |
| ML-792 SUMO E1 inhibitor | Medkoo Biosciences | Cat#407886; CAS:1644342-14-2 |
| NMS-873 p97 inhibitor | Sigma-Aldrich | Cat#SML1128; CAS:1418013-75-8 |
| PHA 767491 Cdc7 inhibitor | Sigma-Aldrich | Cat#PZ0178; CAS:845538-12-7 |
| LacI-biotin | N/A | |
| M.HpaII | N/A | |
| This paper | N/A | |
| Fpg | New England BioLabs | Cat#M0240L |
| UDG | New England BioLabs | Cat#M0280S |
| Human recombinant ubiquitin No Lys | Boston Biochem | Cat#UB-NOK |
| Human recombinant ubiquitin mutant K48R | Boston Biochem | Cat#UM-K48R |
| Human recombinant ubiquitin mutant K63R | Boston Biochem | Cat#UM-K63R |
| Human recombinant ubiquitin mutant K63 only | Boston Biochem | Cat#UM-K630 |
| Human chorionic gonadotropin | Sigma-Aldrich | Cat#CG10-10VL |
| Alpha-32-deoxyadenosinetriphosphate | Perkin Elmer | Cat#BLU512H250UC |
| Gamma-32-adenosinetriphosphate | Perkin Elmer | Cat#BLU502A100UC |
| Gel Loading Buffer II | Thermo Fischer | Cat#AM8547 |
| Lambda exonuclease | New England BioLabs | Cat#M0262S |
| Exonuclease I | New England BioLabs | Cat#M0293S |
| Acc65I restriction enzyme | New England BioLabs | Cat#R0599L |
| HincII restriction enzyme | New England BioLabs | Cat#R0103S |
| SapI restriction enzyme | New England BioLabs | Cat#R0596S |
| Proteinase K, recombinant | Roche | Cat#3115879001 |
| SYBR® Gold Nucleic Acid Gel Stain | Thermo Fisher | Cat#S11494 |
| Phusion® High-Fidelity DNA Polymerase | New England BioLabs | Cat#M0530S |
| Protein A Sepharose Fast Flow | GE Heath Care | Cat#17-1279-01 |
| RNase A | Thermo Fischer | Cat#EN0531 |
| Streptavidin-coupled magnetic beads M-280 | Invitrogen | Cat#11205D |
| Benzonase | Novagen | Cat#70746-3 |
| LysC | Life Technologies | Cat#90051 |
| Trypsin | Life Technologies | Cat#90305 |
| FuGENE 6 Transfection Reagent | Promega | Cat#E2692 |
| Lipofectamine RNAiMAX | Invitrogen | Cat#13778075 |
| Doxycyclin | Sigma-Aldrich | Cat#D9891; CAS: 23390-14-5 |
| Strep-Tactin Sepharose resin | IBA BioTAGnology | Cat#2-1201-010 |
| Blasticidin S | Invitrogen | Cat#ant-bl-1 |
| Hygromycin | Thermo Fisher | Cat#10687010 |
| TnT® Sp6 Quick Coupled Transcription/Translation System | Promega | Cat#L2080 |
| QuickChange II Site directed mutagenesis kit | Agilent | Cat#200524 |
| CHROMASS | This paper; PRIDE partner repository | PRIDE: |
| Total proteome | This paper; PRIDE partner repository | PRIDE: |
| DNA deep sequencing | This paper; European nucleotide archive | ENA: PRJEB39253 |
| Human: U2OS cell line | ATCC | HTB-96 |
| U2OS/Strep-HA-PCNA WT | N/A | |
| U2OS FRT Flp-In TRex | Jakob Nilsson Lab | N/A |
| U2OS/FRT GFP RFWD3 WT siR2 | This paper | N/A |
| U2OS/FRT GFP RFWD3 C315A siR2 | This paper | N/A |
| Nasco | Cat#LM0053MX | |
| Nasco | Cat#LM00715MX | |
| For pFpg: TCA GCA TCC GGT AGC TAC TCA ATC C( | This paper | Tag Copenhagen |
| For pCPD: TGA GGT ACC GGA ( | This paper | TriLink, USA |
| For pAP: TCA GCT AGT TAU AAT AGC CC | This paper | Tag Copenhagen |
| Strand-specific primer DNA library: GGATCCATGTCGCAGTTGCGCA | This paper | Tag Copenhagen |
| Fw primer DNA library: TAGGATCCATCACGCAGTTG | This paper | Tag Copenhagen |
| Fw primer DNA library: TA | This paper | Tag Copenhagen |
| Fw primer DNA library: TA | This paper | Tag Copenhagen |
| Rv primer DNA library: GTCGGGGCTGGCTTAACTATGC | This paper | Tag Copenhagen |
| siCtrl: GGGAUACCUAGACGUUCUA | ( | N/A |
| siRFWD3#2: GGAAACAGGCCGAGUUAGA | N/A | |
| siRFWD3#3: GUUAAGAUGUUGAGUACU | N/A | |
| siRFWD3#4: GGACCUACUUGCAAACUAU | N/A | |
| siRFWD3#601: AACUCCUGCACAUGACUGC | This paper | N/A |
| siRAD18: ACUCAGUGUCCAACUUGCU | N/A | |
| siTRAIP: CCGUGAUGAUAUUGAUCUCAA | ( | N/A |
| siGENOME Human SHPRH siRNA | Dharmacon | N/A |
| siGENOME Human HLTF siRNA | Dharmacon | N/A |
| pJLS2 | N/A | |
| pNBL101 | N/A | |
| pFpg | This paper | N/A |
| pCPD | This paper | N/A |
| pAP | This paper | N/A |
| pCMV-Sport- | This paper | N/A |
| pcDNA4/TO Strep HA PCNA WT | N/A | |
| pcDNA4/TO Strep HA PCNA K164R | N/A | |
| pcDNA5 FRT/TO GFP-RFWD3 WT | N/A | |
| pcDNA5 FRT/TO GFP-RFWD3 C315A | N/A | |
| pcDNA5 FRT/TO GFP-RFWD3 I639K | N/A | |
| pcDNA5 FRT/TO GFP-RFWD3 WT siR2 | This paper | N/A |
| pcDNA5 FRT/TO GFP-RFWD3 C315A siR2 | This paper | N/A |
| pcDNA5 FRT/TO GFP-RFWD3 I639K siR2 | This paper | N/A |
| pOG44 | Invitrogen | Cat#V600520 |
| pQuant | ( | N/A |
| ImageJ | NIH | |
| AdapterRemoval | ||
| samtools | ||
| Picard | Broad Institute, GitHub repository. | |
| MaxQuant | ( | |
| Perseus | ( | |